psmarketresearch1’s blog

All about market research update

mTOR Inhibitors Market - Global Industry Analysis, Size, Growth and Demand, 2023


The global mammalian target of rapamycin inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.

Explore Report at:

The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.

Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.

Europe is the second largest market for mTOR inhibitors. During the forecast period, the mTOR inhibitors market would witness highest growth in Asia-Pacific, attributed to increasing number of new entrants, improving healthcare infrastructure, increasing prevalence of chroic diseases and increasing healthcare expenditure.

Request for Report Sample at:

The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

Ocular Pain Treatment Market - Pipeline Analysis, Share and Forecast to 2023


The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.

Explore Full Report Description with Detailed TOC at:

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

A large number of pharmaceutical companies are constantly working for the research and development of ocular pain treatment. However, certain factors such as high treatment cost, less awareness about the eye disease among population and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.

Request for Report Sample at:

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.

Personalized Medicine Market - Global Industry Analysis, Size, Growth and Demand, 2023


The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.

Request for Report Sample at:

The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.

National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.

Explore Full Report Description with Detailed TOC at:

Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Cardiovascular Devices Market Trends, Size, Growth and Demand, 2023


Cardiovascular devices are used to treat cardiovascular diseases that include numerous problems, most of them related to atherosclerosis. Atherosclerosis is a medication state characterized by when a substance called plaque builds up in the walls of the arteries. It narrows the arteries, making it harder for blood to flow through and affects the normal supply of blood and causes heart attack. Heart attack occurs when the blood flow of the heart is blocked by a blood clot. Other cardiovascular diseases, such as ischemic stroke and heart failure, occur when a blood vessel is blocked by clot. In addition, heart failure, sometimes called congestive heart failure, means the heart isn't pumping blood properly. Arrhythmia is also one of the major cardiovascular diseases usually characterized by abnormal rhythm of the heart. To overcome these problems, various cardiovascular devices are used to diagnose and treat heart diseases.

For more information visit:

The global cardiovascular devices is segmented into cardiac rhythm management, cardiovascular monitoring and diagnostic, interventional cardiology, prosthetic heart valves, external defibrillators, electrophysiology, peripheral vascular, cardiac assist and cardiovascular prosthetic and cardiovascular surgery. Cardiac rhythm management device is the largest segment in global cardiovascular devices market.

North America accounts for the largest cardiovascular devices market followed by Europe. This is due to increased awareness about various heart diseases, developed economies and increased overweight or obese people in the region. In addition, high disposable incomes and favorable reimbursement policies are also supporting the growth of cardiovascular devices market in the region. The U.S., followed by Canada, is the largest market for cardiovascular devices in North America. Germany, France and the U.K. are some of the largest markets for cardiovascular devices in the European region. However, Asia-Pacific represents the fastest growing region in the global cardiovascular devices market. This is due to increasing awareness about various heart diseases in the region and increasing number of aged people in the region.

Explore Report Sample at:

However, stringent regulations and legislations is a key restraint of the global cardiovascular devices market. In addition, high cost of cardiovascular devices and lack of skilled healthcare professionals to operate expensive devices also obstructs growth of cardiovascular devices. Rapid product launches and increasing mergers and acquisitions between cardiovascular devices manufacturing companies are key trends in global cardiovascular devices market.

Some of the major competitors in the market are Medtronic Inc., MAQUET GmbH & Co. KG, Sorin Group, Terumo Corporation, C. R. Bard Inc., SEMMT Inc., Cardima Inc. CyberHeart Incorporated, Kardium Inc., EndoPhotonix Inc., St. Jude Medical, MedWaves Incorporated and Edwards Lifesciences.

Acute Ischemic Stroke Diagnosis and Treatment Market Size, Forecast to 2023


Acute ischemic stroke refers to a sudden loss of certain brain function owing to uneven or lack of blood to the brain. Acute ischemic functions are mainly triggered by atherosclerosis plaques blocking blood vessels, blood clots locking the blood distribution to or from arteries nourishing the brain, or narrowing of blood vessels of the brain. Acute ischemic stroke is one of the major causes of permanent disability in the patients. It is also the third largest reason of death worldwide. Acute ischemic stroke can affect persons of all age groups. However, acute ischemic stroke most commonly affects the individuals, who are above 60 years, the risk of acute ischemic stroke increases with age. Driven by the technical advancement in diagnosis, the acute ischemic stroke diagnosis and treatment demand is expected to experience an escalating demand in coming years.

Request for Report Sample at:

The advancements in the surgical devices technology, in addition with the rising occurrence of acute ischemia stroke cases among the patients are some of the dominant driving factor for the surgery in acute stroke treatment. Some of the other factors driving the market include, aging population mainly in the developed countries of Europe and North America. The development of the effective medication in the treatment of ischemic stroke is accepted to hinder the acceptance of expensive surgery in the ischemic stroke diagnosis market. The development of desmoteplase, a novel next-generation thrombolytic, is one of the major advancement of in the treatment technology of acute ischemic stroke. It provides extended therapeutic time compared to most of the other treatment procedure. Moreover, with the increasing impact of telemedicine and e-prescription and e-medical adherence the acute ischemic stroke diagnosis and treatment market is expected to flourish at a healthy rate during the forecast period.

North America was the largest market of acute ischemic stroke diagnosis and treatment in 2014. The market dominance of the North America is attributed to high percentage of patients suffering from strokes, in admiration with the technical advancement in the treatment procedure acute ischemic stroke in the region. It is then followed by Europe; the large population of baby boomers in Europe is one of the factors for a high market share in acute ischemic stroke diagnosis and treatment market. Country wise, the U.S., Canada are two of the major markets in North America. Germany, Italy, the U.K, and France are some of the dominant market in Europe, Japan, China and India are the major market of Asia Pacific region.

To know more visit:

Some of the leading players operating in global acute ischemic stroke diagnosis and treatment  market include, Abbott Laboratories, Covidien plc, Johnson & Johnson (Cordis Corporation), Penumbra, Inc., Philips Healthcare, GE Healthcare, Hitachi, Ltd., Siemens Healthcare, and Stryker Corporation (Concentric Medical, Inc.).

Capsule Endoscopes Market - Global Market Size, Share and Demand, 2023


Global capsule endoscopes market is growing with a significant rate due to demand for faster and accurate diagnostic tools, for managing the rising prevalence of gastrointestinal diseases, colorectal cancer, and government initiatives. Moreover, increasing aging population and introduction of technologically advanced capsules such as Wi-Fi enabled capsule and longer battery life capsule are expected to support the capsule endoscopes market to grow in the coming years. Aging increases the risk of gastrointestinal disorders, such as inflammatory bowel disease, CRC, and appendicitis.

Explore Report Sample at:

According to the World Health Organization, the population of 60 years and above is expected to rise to 15% in 2050. Peptic ulcers are general in elderly people and are mostly caused due to prolonged usage of H, Pylori infection and non-steroidal anti-inflammatory drugs (NSAIDS). Some of the patients suffering from ulcers have serious complications and sometimes it becomes life threatening for them. This is expected to expand the patient base, resulting in the growth of the capsule endoscopes market. Moreover, the use of hybrid and magnetic capsules to enable enhanced imaging and better control are ongoing research attributes, which is further expected to support the capsule endoscopes market to grow in the coming years.

North America leads the capsule endoscopes market, due to the presence of favorable reimbursement policies, rising prevalence rate of gastrointestinal disorders and colorectal cancer, increasing adoption of minimally invasive capsule endoscopy by patients and advanced healthcare infrastructure in the region. Asia-Pacific is expected to grow with the highest rate in the coming years, due to increasing disposable income, increasing patient awareness levels, presence of untapped opportunities regarding cancer screening and improving healthcare infrastructure.

Explore more about “global capsule endoscopes market” at:

Healthcare professionals and patients are shifting from conventional methods, such double balloon enteroscopy to the capsule endoscopes. All this is due to benefits from capsule endoscopes such as a real time image of the entire small intestine, quick and easy diagnosis, providing extensive growth to the capsule endoscopes market in the coming years.

Some of the competitors in the capsule endoscopes market are Olympus Corporation, Capso Vision Inc., Chongqing Jinshan Science & Technology Co., RF System lab, Fujifilm Holding Corporation, Given Imaging Ltd., and IntroMedic Co., Ltd.

Browse Other Related Report at:

Skincare Devices Market Size, Trends, Analysis and Forecast to 2023


The skincare devices market is growing at a significant rate, due to increasing preference of minimally and non-invasive procedures, growing medical tourism, and increasing worldwide incidence rate of skin disorders. Untapped market potential in emerging economies with high unaddressed medical needs is providing ample opportunities for the global skincare devices market to grow in the coming years.

Explore Report Sample at:

Some of the major factors driving the growth of the skincare devices market are manufacturing of more advanced and affordable devices such as, ultrasonic and exfoliating devices for the consumers. Rising incidences of skin cancer and various skin disorders such as, acne, dermatitis, lesions, moles, psoriasis and skin warts, mainly in emerging markets of China, India and Brazil are expected to support the growth of skincare devices market in the coming years. The skin-care segment has seen higher investment by beauty products manufacturer, in recent years for the products having highest consumer inclination.

Additionally, increasing acceptance rate of non-invasive and minimal treatments, increasing consumer awareness levels and increasing demand for aesthetic processes such as, skin tightening, skin rejuvenation and body contouring are some of the factors, expected to drive the growth of the skincare devices market in the coming years. Substitutes of the skincare devices gaining popularity, competitive pricing, and equipment costs are some of the factors restraining the growth of skincare devices market.

Explore more about “Skincare Devices Market” at:

The skincare devices market can also be categorized, on the basis of applications as damage repair, skin rejuvenation, anti-cellulite skincare, disease diagnosis and treatment, fat reduction, hair removal, and skin tightening and body contouring. Skin rejuvenation includes sun damage, acne and wrinkles, whereas damage repair includes pigmented lesions, vascular and tattoo removal. Body contouring and skin tightening market leads in the application of skincare devices market, due to the rising demand for non-surgical, non-invasive and no downtime treatments. Anti-cellulite skincare application is growing with the highest rate, due to establishment of new product range such as fat melting oil, ayurvedic anti cellulite cream, anti-cellulite oil and slimming oil.